[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 69 of about 69
1. Pinheiro GS, Silva MR, Rodrigues CA, Kerbauy J, de Oliveira JS: Proliferating cell nuclear antigen (PCNA), p53 and MDM2 expression in Hodgkins disease. Sao Paulo Med J; 2007 Mar 1;125(2):77-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferating cell nuclear antigen (PCNA), p53 and MDM2 expression in Hodgkins disease.
  • CONTEXT AND OBJECTIVE: Tumor cells in Hodgkins disease (HD) express cell proliferation markers that are evaluated according to the oncogenes involved or the expression of their proteins.
  • Correlations between the protein expression grade and clinical data are now important for disease prognosis.
  • DESIGN AND SETTING: This was a retrospective analysis on proliferating cell nuclear antigen (PCNA), p53 and MDM2 (murine double minute-2) expression using immunohistochemistry, on formalin-fixed, paraffin-embedded tissues from diagnostic biopsies on 51 patients with HD.
  • The study was conducted at the Division of Hematology and Transfusion Medicine, Hospital São Paulo, Universidade Federal de São Paulo.
  • METHODS: Antigen expression was evaluated as the proportions of positive Hodgkin and Reed-Sternberg (HRS) cells and reactive lymphocytes (L), which were compared using Spearman correlation coefficients.
  • CONCLUSIONS: PCNA, p53 and MDM2 are tumor markers for HD, but showed no clinical or prognostic significance in our analysis.
  • [MeSH-major] Hodgkin Disease / metabolism. Proliferating Cell Nuclear Antigen / analysis. Proto-Oncogene Proteins c-mdm2 / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Epidemiologic Methods. Female. Humans. Lymphocytes / pathology. Male. Middle Aged. Prognosis. Reed-Sternberg Cells / chemistry

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625704.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


2. Fosså SD, Holte H, Holmen MM, Bjøro T, Langmark F, Hess SL, Kvaløy S: [Long-term effects after mantle field radiotherapy for Hodgkin's lymphoma]. Tidsskr Nor Laegeforen; 2005 Jan 6;125(1):41-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term effects after mantle field radiotherapy for Hodgkin's lymphoma].
  • [Transliterated title] Langtidseffekter etter kappefeltsbehandling for Hodgkins lymfom.
  • METHODS: 78 women who 10 years or more ago at an age of below 40 had received mantle field radiotherapy for Hodgkin's lymphoma were examined for breast cancer and general health problems.
  • [MeSH-major] Health Status. Hodgkin Disease / radiotherapy. Radiotherapy / adverse effects. Survivors
  • [MeSH-minor] Adult. Breast Neoplasms / etiology. Female. Humans. Neoplasms, Radiation-Induced / etiology. Risk Factors. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643464.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


3. Cozen W, Gill PS, Salam MT, Nieters A, Masood R, Cockburn MG, Gauderman WJ, Martínez-Maza O, Nathwani BN, Pike MC, Van Den Berg DJ, Hamilton AS, Deapen DM, Mack TM: Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood; 2008 Apr 1;111(7):3377-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma.
  • Young adult Hodgkin lymphoma (YAHL) is associated clinically with altered immunity, including a systemic defect in cell-mediated responses.
  • We identified twin pairs in whom at least one member had YAHL and measured interleukin-2 (IL-2), interleukin-12 (IL-12), and interferon-gamma (IFN-gamma) levels in PHA-stimulated peripheral blood mononuclear cell supernatant in 90 case-twins, 84 of their disease-free twins (unaffected cotwins), and 90 matched controls.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 Oct 15;175(8):5457-62 [16210653.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1506-10 [11069557.001]
  • [Cites] Genes Immun. 2000 Dec;1(8):515-20 [11197695.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):218-21 [11175794.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):675-80 [11477402.001]
  • [Cites] Twin Res. 2001 Aug;4(4):242-50 [11665304.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):69-75 [11905816.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):624-30 [12594818.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):545-52 [12845650.001]
  • [Cites] Leuk Lymphoma. 2003 Aug;44(8):1325-31 [12952225.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):248-50 [831107.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Biometrics. 1982 Sep;38(3):715-24 [7171697.001]
  • [Cites] Semin Oncol. 1990 Dec;17(6):673-82 [2251514.001]
  • [Cites] Nature. 1996 Jul 11;382(6587):174-7 [8700209.001]
  • [Cites] J Immunol. 1997 Aug 15;159(4):1658-65 [9257825.001]
  • [Cites] Genes Immun. 2004 Dec;5(8):675-7 [15483662.001]
  • [Cites] Hum Immunol. 2004 Dec;65(12):1432-6 [15603869.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):493-5 [15686457.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):740-8 [15643599.001]
  • [Cites] Genes Immun. 2005 Mar;6(2):167-70 [15674372.001]
  • [Cites] Intensive Care Med. 2005 Mar;31(3):401-7 [15719148.001]
  • [Cites] Cytokine. 2005 May 21;30(4):188-94 [15863393.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2006 Feb;61(2):125-35 [16510856.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2062-3 [16990781.001]
  • [Cites] Genes Immun. 2006 Dec;7(8):615-24 [16971956.001]
  • [Cites] Twin Res. 2000 Mar;3(1):33-42 [10808239.001]
  • (PMID = 18077789.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA110836; United States / NCI NIH HHS / CA / 1R01CA58839; United States / NCI NIH HHS / CA / 1R03CA110836
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2275007
  •  go-up   go-down


Advertisement
4. Govender PS, Moodley M: Primary non-Hodgkins lymphoma of the ovary in the background of human immunodeficiency virus (HIV): a bold and curative approach to treatment. Eur J Gynaecol Oncol; 2010;31(1):102-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkins lymphoma of the ovary in the background of human immunodeficiency virus (HIV): a bold and curative approach to treatment.
  • Non-Hodgkins lymphoma of the ovary is a rare disease and there is only one previously documented case arising in a patient with human immunodeficiency virus (HIV).
  • In this report, the authors discuss the management of a case of non-Hodgkins Lymphoma of the ovary occurring in a patient with HIV and demonstrate that treatment regimens may be successfully implemented in this immunocompromised population without an increase in adverse effects.
  • [MeSH-major] HIV Infections / complications. Lymphoma, Non-Hodgkin / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Female. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349792.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Munshi A, Pandey MB, Kumar L, Karak AK, Mohanti BK: A case of Hodgkin's disease presenting with recurrent laryngeal nerve palsy and tracheoesophageal fistula. Med J Malaysia; 2006 Mar;61(1):97-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Hodgkin's disease presenting with recurrent laryngeal nerve palsy and tracheoesophageal fistula.
  • Hodgkins disease rarely leads to such a fistula.
  • We report a case of Hodgkin's disease with a tracheoesophageal fistula as well as a left recurrent nerve palsy at presentation.
  • On follow up 1 year after the completion of treatment, he was clinically and radiologically disease free.
  • [MeSH-major] Hodgkin Disease / diagnosis. Recurrent Laryngeal Nerve / pathology. Tracheoesophageal Fistula / diagnosis. Vocal Cord Paralysis / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Recurrence

  • Genetic Alliance. consumer health - Tracheoesophageal fistula.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708743.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


6. Hobbie WL, Ginsberg JP, Ogle SK, Carlson CA, Meadows AT: Fertility in males treated for Hodgkins disease with COPP/ABV hybrid. Pediatr Blood Cancer; 2005 Feb;44(2):193-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility in males treated for Hodgkins disease with COPP/ABV hybrid.
  • More than 80% of those diagnosed with Hodgkins disease (HD) will survive long-term.
  • For the past decade, a modified hybrid consisting of cyclophosphamide (2.4-3.6g/m(2)), vincristine, procarbazine, and prednisone (COPP) together with adriamycin, bleomycin, and vinblastine (ABV) has been used to treat patients with HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fertility / drug effects. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Bleomycin / adverse effects. Child. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Humans. Male. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15390272.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00240
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COPP protocol; VBA protocol
  •  go-up   go-down


7. Cozen W, Hamilton AS, Zhao P, Salam MT, Deapen DM, Nathwani BN, Weiss LM, Mack TM: A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma. Blood; 2009 Nov 5;114(19):4014-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma.
  • The pattern of adolescent/young adult Hodgkin lymphoma (YAHL) suggests causation by a relatively late infection with a common childhood virus, but no causal virus has been found.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1506-10 [11069557.001]
  • [Cites] Twin Res. 2000 Mar;3(1):33-42 [10808239.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Am J Epidemiol. 2002 Dec 1;156(11):1011-20 [12446257.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):624-30 [12594818.001]
  • [Cites] N Engl J Med. 2003 Jun 5;348(23):2313-22 [12788995.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3216-21 [15070705.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):387-97 [15141139.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2271-81 [15181575.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S27-32 [15202522.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1361-70 [15298959.001]
  • [Cites] J Natl Cancer Inst. 1973 Jun;50(6):1429-35 [4717560.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Br Med J. 1978 Feb 11;1(6109):327-9 [623979.001]
  • [Cites] Cancer Res. 1979 Nov;39(11):4507-11 [498082.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] J Clin Epidemiol. 1989;42(12):1207-13 [2585011.001]
  • [Cites] J Clin Gastroenterol. 1990 Apr;12(2):127-9 [2157745.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):261-8 [1303125.001]
  • [Cites] N Engl J Med. 1995 Feb 16;332(7):413-8 [7824015.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):977-81 [9378561.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1045-7 [9569037.001]
  • [Cites] Clin Exp Allergy. 1999 Mar;29(3):342-6 [10202341.001]
  • [Cites] Lancet. 1999 Sep;354 Suppl 2:SII12-5 [10507253.001]
  • [Cites] J Clin Immunol. 2004 Nov;24(6):617-22 [15622446.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):89-93 [16309494.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] Int J Dermatol. 2006 Mar;45(3):251-6 [16533224.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2382-8 [17332371.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Neurology. 2007 Jul 24;69(4):381-8 [17646631.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1561-6 [17684129.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3377-82 [18077789.001]
  • [Cites] BMC Immunol. 2008;9:65 [18990206.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1259-65 [1661073.001]
  • [Cites] Clin Exp Allergy. 2000 Nov;30(11):1590-6 [11069568.001]
  • (PMID = 19738032.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA110836; United States / NCI NIH HHS / CA / 1R01CA58839; United States / NCI NIH HHS / CA / 1R03CA110836-01A2; United States / NCI NIH HHS / CA / R03CA110836-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL6 protein, human; 0 / Interleukin-6; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC2774542
  •  go-up   go-down


8. Kim HJ, Kim AY, Lee CW, Yu CS, Kim JS, Kim PN, Lee MG, Ha HK: Hirschsprung disease and hypoganglionosis in adults: radiologic findings and differentiation. Radiology; 2008 May;247(2):428-34
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hirschsprung disease and hypoganglionosis in adults: radiologic findings and differentiation.
  • PURPOSE: To retrospectively evaluate the imaging features of adult Hirschsprung disease (HD) and adult hypoganglionosis (HG) and to compare these features with histopathologic findings.
  • The imaging, medical, and histopathologic data of 10 patients (seven women, three men; mean age, 38 years) with histopathologically proved adult HD and/or adult HG were reviewed.
  • The CT findings of HD and HG were compared by using the Mann-Whitney U test.
  • The transition zone ratio was significantly different between the patients with HD (median ratio, 4.0) and the patients with HG (median ratio, 2.0) (P = .016).
  • However, there was no significant difference in the longitudinal length of the transition zone between the two patient groups (median ratios, 4.4 cm for HD group and 6.0 cm for HG group; P = .190).
  • CONCLUSION: A markedly dilated proximal colonic segment with a transition zone and a narrowed distal colonic segment on CT and double-contrast barium enema images in conjunction with chronic refractory constipation in an adult should suggest the diagnosis of adult HD or adult HG.
  • The detection of a much higher transition zone ratio may help to establish the diagnosis of HD.
  • [MeSH-major] Colon / innervation. Colon / radiography. Hirschsprung Disease / radiography
  • [MeSH-minor] Adult. Barium Sulfate. Contrast Media. Diagnosis, Differential. Enema. Female. Ganglia, Autonomic / pathology. Humans. Iohexol / analogs & derivatives. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18430875.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


9. Gabriel I, Apperley J, Bower M, Chaidos A, Gazzard B, Giles C, Kew A, Nelson M, Kanfer E: A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease. AIDS; 2008 Feb 19;22(4):539-40
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease.
  • A 44-year-old man with relapsed HIV-associated stage IV nodular sclerosing Hodgkin's disease underwent high-dose therapy with autologous stem cell transplantation.
  • Autologous stem cell transplantation is safe in HIV patients and can achieve long-term durable remissions in Hodgkin's disease.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cell Transplantation / methods. Hodgkin Disease / therapy. Lymphoma, AIDS-Related / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Humans. Lomustine / administration & dosage. Male. Remission Induction / methods. Transplantation, Autologous

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301069.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


10. Al-Mulhim FA: Magnetic resonance imaging of pelvic and femoral bones for detection of bone marrow infiltration in patients with non-Hodgkins lymphoma. Saudi Med J; 2005 Jan;26(1):31-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of pelvic and femoral bones for detection of bone marrow infiltration in patients with non-Hodgkins lymphoma.
  • OBJECTIVE: Detection of the residual bone marrow (BM) involvement is essential in treatment of patients with non-Hodgkin's lymphoma (NHL).
  • This study was conducted to determine the advantage of femoral marrow MRI as a non-invasive technique over bilateral iliac crest BM biopsies in detecting BM infiltration before treatment and residual disease after completion of treatment.
  • [MeSH-major] Bone Marrow / pathology. Femur / pathology. Lymphoma, Non-Hodgkin / pathology. Magnetic Resonance Imaging. Pelvis / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Saudi Med J. 2005 May;26(5):898
  • (PMID = 15756349.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


11. Rüffer JU, Ballova V, Glossmann J, Sieber M, Franklin J, Nogova L, Diehl V, Josting A, German Hodgkin Study Group: BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leuk Lymphoma; 2005 Nov;46(11):1561-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.
  • Patients with early stage favorable Hodgkin's disease who relapse after extended field radiotherapy have satisfactory results.
  • We retrospectively analysed patients with relapsed HD after initial radiation therapy alone to determine treatment outcome and prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Databases, Factual. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiation Dosage. Radiotherapy / methods. Remission Induction. Retrospective Studies. Survival Analysis. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236610.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol; CVPPABO protocol
  •  go-up   go-down


12. Harris RE, Beebe-Donk J, Doss H, Burr Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep; 2005 Apr;13(4):559-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial epidemiologic studies of malignant melanoma, Hodgkin's disease, and adult leukemia also found that NSAIDs are protective.
  • [MeSH-minor] Animals. Case-Control Studies. Cohort Studies. Cyclooxygenase 1. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Disease Models, Animal. Female. Humans. Male. Membrane Proteins. Models, Biological. Risk. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IBUPROFEN .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2005 Aug;174(2):787-8 [16006977.001]
  • (PMID = 15756426.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Anticarcinogenic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; R16CO5Y76E / Aspirin; WK2XYI10QM / Ibuprofen
  • [Number-of-references] 264
  •  go-up   go-down


13. Freed J, Kelly KM: Current approaches to the management of pediatric Hodgkin lymphoma. Paediatr Drugs; 2010 Apr 1;12(2):85-98
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current approaches to the management of pediatric Hodgkin lymphoma.
  • Hodgkin lymphoma is one of the few cancers that affect both adults and children.
  • Cure rates for Hodgkin lymphoma remain among the best for pediatric cancers.
  • At diagnosis, patients are classified into risk groups based on disease stage, and the presence of clinical, biologic, and serologic risk factors.
  • In general, the most recent trials have intensified therapy in those patients with high-risk disease to improve disease control, and have limited therapy in those patients with low-risk disease to avoid secondary effects.
  • In addition, response assessment by fluorine-18-2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) may be particularly important in pediatric Hodgkin lymphoma; it may allow modification of treatment to maximize treatment efficacy and minimize late effects of chemotherapy and radiation therapy.
  • Despite the improvements in treatment for all stages of Hodgkin lymphoma, there is still a subgroup of patients who do not enter remission with initial therapy or relapse after initial response to therapy.
  • Unfortunately, standard-dose salvage chemotherapy for relapsed disease has disappointing results in terms of overall survival since patients have typically already received intensive therapy.
  • While there is no standard of care in terms of salvage chemotherapy, high-dose chemotherapy with autologous stem cell transplant (ASCT) rescue has become the standard of care for the majority of children with relapsed Hodgkin lymphoma.
  • The use of allogeneic transplantation is controversial in relapsed or refractory Hodgkin lymphoma; because of the high transplant-related mortality, allogeneic transplant has not been associated with improved overall survival over ASCT.
  • As more has been learned about the biologic mechanisms involved in Hodgkin lymphoma, biologically-based therapies are being investigated for use in this disease, both at initial diagnosis and relapse.
  • Both immunotherapy and small molecules are being studied as possible therapeutic agents in Hodgkin lymphoma.
  • Unfortunately, the vast majority of investigations of novel agents have occurred exclusively in adult patients.
  • However, since pediatric Hodgkin lymphoma and adult Hodgkin lymphoma are similar, these results may potentially be extrapolated to pediatric Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hodgkin Disease / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Child. Combined Modality Therapy. Disease-Free Survival. Humans. Neoplasm Staging. Remission Induction / methods. Risk Factors. Salvage Therapy / methods. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20218745.001).
  • [ISSN] 1179-2019
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 73
  •  go-up   go-down


14. Mlczoch L, Attarbaschi A, Dworzak M, Gadner H, Mann G: Alopecia areata and multifocal bone involvement in a young adult with Hodgkin's disease. Leuk Lymphoma; 2005 Apr;46(4):623-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alopecia areata and multifocal bone involvement in a young adult with Hodgkin's disease.
  • Staging procedures revealed multifocal bone disease and generalized lymphadenopathy.
  • The diagnosis of nodular sclerosing Hodgkin's disease was established by biopsies of the os ileum and a left inguinal lymph node.
  • Conclusively, this case illustrates that alopecia areata may occur as a paraneoplastic phenomenon or an autoimmune process related to the deranged cellular immune system in children and adolescents with Hodgkin's disease.
  • [MeSH-major] Alopecia Areata / complications. Bone Neoplasms / complications. Hodgkin Disease / complications

  • Genetic Alliance. consumer health - Alopecia Areata.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019495.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Salgado OJ, Terán NA, Rosales B, Garcia RA: Subcutaneous transposition of the superficial femoral artery for arterioarterial hemodialysis: technique and results. Artif Organs; 2008 Dec;32(12):969-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the use of subcutaneous transposition of the femoral artery (STFA) for placement of both inflow and outflow needles in 14 hemodialysis (HD) adult patients with difficult access.
  • Follow-up time was 318 months during which a total of 3215 arterioarterial HD sessions were done.
  • [MeSH-minor] Adult. Aneurysm / etiology. Aneurysm, False / etiology. Constriction, Pathologic / etiology. Female. Follow-Up Studies. Hemorrhage / etiology. Humans. Infection / etiology. Male. Middle Aged. Outcome Assessment (Health Care). Thrombosis / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133026.001).
  • [ISSN] 1525-1594
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Roper K, McDermott K, Cooley ME, Daley K, Fawcett J: Health-related quality of life in adults with Hodgkin's disease: the state of the science. Cancer Nurs; 2009 Nov-Dec;32(6):E1-17; quiz E18-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life in adults with Hodgkin's disease: the state of the science.
  • Hodgkin's disease (HD) affects younger and older adults and can disrupt developmental tasks and cause multiple medical sequelae.
  • This article is an integrative review of empirical studies of HRQOL in HD survivors.
  • Commonly reported physical consequences of HD include fatigue, anticipatory nausea and vomiting, and cognitive problems that lasted several years after treatment completion, as well as long-term life-threatening adverse effects including secondary cancers and cardiovascular and respiratory complications.
  • Development of appropriate theory-guided interventions to improve the HRQOL for HD survivors can be achieved through more rigorous study designs and standardization of HRQOL measurements.
  • [MeSH-major] Education, Nursing, Graduate / standards. Hodgkin Disease / psychology. Oncology Nursing / education. Quality of Life / psychology
  • [MeSH-minor] Adaptation, Psychological. Adult. Humans. Survivors / psychology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19816166.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 U56 CA11863502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


17. Okuno K, Horie Y, Kanai K, Kato M, Kuwamoto S, Okazaki T, Hayashi K: Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia. J Clin Exp Hematop; 2009 May;49(1):45-51
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus associated post-transplant Hodgkin lymphoma in an adult patient after cord blood stem cell transplantation for acute lymphoblastic leukemia.
  • Although post-transplant Hodgkin lymphoma (HL) is included in PTLD, there have been no studies in the literature on adult cases of post-transplant HL after cord blood stem cell transplantation (CBSCT).
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Hodgkin Disease / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Diagnosis, Differential. Epstein-Barr Virus Infections / etiology. Female. Herpesvirus 4, Human. Humans. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Treatment Outcome. Young Adult


18. Belgaumi AF: Hodgkin's lymphoma in the young child. Transfus Apher Sci; 2010 Apr;42(2):163-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in the young child.
  • Primarily a disease of adults, Hodgkin's lymphoma (HL) contributes significantly to pediatric malignant diseases, particularly in developing countries where the incidence is higher.
  • Patients with advanced disease have lower outcomes, which have improved with chemotherapy intensification.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Pediatrics

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20100668.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Bober SL, Park ER, Schmookler T, Medeiros Nancarrow C, Diller L: Perceptions of breast cancer risk and cancer screening: a qualitative study of young, female Hodgkin's disease survivors. J Cancer Educ; 2007;22(1):42-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perceptions of breast cancer risk and cancer screening: a qualitative study of young, female Hodgkin's disease survivors.
  • BACKGROUND: Young female Hodgkins Disease (HD) survivors are at high risk for breast cancer following chest irradiation.
  • CONCLUSION: Female HD survivors would likely benefit from tailored education that links current beliefs with their previous cancer experience.
  • Education about cancer risk may be more effective if delivered in a health-promoting rather than disease-detection framework.
  • [MeSH-major] Breast Neoplasms / prevention & control. Hodgkin Disease / radiotherapy. Mass Screening. Neoplasms, Second Primary / prevention & control. Survivors
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Mammography. Prospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17570808.001).
  • [ISSN] 0885-8195
  • [Journal-full-title] Journal of cancer education : the official journal of the American Association for Cancer Education
  • [ISO-abbreviation] J Cancer Educ
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Margolis RL, Rudnicki DD, Holmes SE: Huntington's disease like-2: review and update. Acta Neurol Taiwan; 2005 Mar;14(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huntington's disease like-2: review and update.
  • Huntington's Disease-like 2 (HDL2), like Huntington's disease (HD), is an adult onset, progressive, neurodegenerative autosomal dominant disorder clinically characterized by abnormal movements, dementia, and psychiatric syndromes.
  • Like HD, the neuropathology of HDL2 features prominent cortical and striatal atrophy and intranuclear inclusions.
  • HDL2 is generally rare, accounting for only a few percent of HD-like cases in which the HD mutation has already been excluded.
  • However, the rate is considerably higher among individuals of African ancestry, and is almost as common as HD in Black South Africans.
  • The disorder is caused by a CTG/CAG expansion mutation on chromosome 16q24.3, with normal and expanded repeat ranges similar to HD, and a correlation between repeat length and onset age very similar to HD.
  • Surprisingly, the available evidence suggests that HDL2 is not a polyglutamine disease.
  • The phenotypic similarities between HD and HDL2 suggest that understanding the pathobiology of HDL2 may shed new light on the pathogenesis of HD and other disorders of striatal neurodegeneration.
  • [MeSH-major] Huntington Disease / genetics

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15835282.001).
  • [ISSN] 1028-768X
  • [Journal-full-title] Acta neurologica Taiwanica
  • [ISO-abbreviation] Acta Neurol Taiwan
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS16375
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / junctophilin
  • [Number-of-references] 48
  •  go-up   go-down


21. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet; 2009 Jan 10;373(9658):125-36
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systematic pelvic lymphadenectomy has been used to establish whether there is extra-uterine disease and as a therapeutic procedure; however, randomised trials need to be done to assess therapeutic efficacy.
  • To control for postsurgical treatment, women with early-stage disease at intermediate or high risk of recurrence were randomised (independent of lymph-node status) into the ASTEC radiotherapy trial.
  • 251 women died or had recurrent disease (107 standard surgery group, 144 lymphadenectomy group), with an HR of 1.35 (1.06-1.73; p=0.017) in favour of standard surgery and an absolute difference in 5-year recurrence-free survival of 6% (1-12).

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1984 Jun;63(6):825-32 [6728365.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16 [19033573.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1595-604 [17347128.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1823-30 [16977653.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):92-7 [16406063.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3668-75 [15738538.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):340-3 [9887227.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):371-4 [11531297.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:179-202 [14763175.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):137-46 [19070891.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Aug;96(8):889-92 [2775686.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):29-33 [7821843.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):165-71 [9740684.001]
  • [CommentIn] Lancet. 2009 Apr 4;373(9670):1169; author reply 1170-1 [19345821.001]
  • [CommentIn] Future Oncol. 2009 May;5(4):459-63 [19450175.001]
  • [CommentIn] Lancet. 2009 Apr 4;373(9670):1169-70; author reply 1170-1 [19345819.001]
  • [CommentIn] Lancet. 2009 Apr 4;373(9670):1169; author reply 1170-1 [19345820.001]
  • [CommentIn] Lancet. 2009 Apr 4;373(9670):1170; author reply 1170-1 [19345823.001]
  • [CommentIn] Lancet. 2009 Jan 10;373(9658):97-9 [19070890.001]
  • [ErratumIn] Lancet. 2009 May 23;373(9677):1764
  • (PMID = 19070889.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] ENG
  • [Databank-accession-numbers] ISRCTN/ ISRCTN16571884
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122861379; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2646126
  • [Investigator] Amos C; Blake P; Branson A; Buckley CH; Redman CW; Shepherd J; Dunn G; Heintz P; Yarnold J; Johnson P; Mason M; Rudd R; Badman P; Begum S; Chadwick N; Collins S; Goodall K; Jenkins J; Law K; Mook P; Sandercock J; Goldstein C; Uscinska B; Cruickshank M; Parkin DE; Crawford RA; Latimer J; Michel M; Clarke J; Dobbs S; McClelland RJ; Price JH; Chan KK; Mann C; Rand R; Fish A; Lamb M; Goodfellow C; Tahir S; Smith JR; Gornall R; Kerr-Wilson R; Swingler GR; Lavery BA; Chan KK; Kehoe S; Flavin A; Eddy J; Davies-Humphries J; Hocking M; Sant-Cassia LJ; Pearson S; Chapman RL; Hodgkins J; Scott I; Guthrie D; Persic M; Daniel FN; Yiannakis D; Alloub MI; Gilbert L; Heslip MR; Nordin A; Smart G; Cowie V; Katesmark M; Murray P; Eddy J; Gornall R; Swingler GR; Finn CB; Moloney M; Farthing A; Hanoch J; Mason PW; McIndoe A; Soutter WP; Tebbutt H; Morgan JS; Vasey D; Cruickshank DJ; Nevin J; Kehoe S; McKenzie IZ; Gie C; Davies Q; Ireland D; Kirwan P; Davies Q; Lamb M; Kingston R; Kirwan J; Herod J; Fiander A; Lim K; Head AC; Lynch CB; Browning AJ; Cox C; Murphy D; Duncan ID; Mckenzie C; Crocker S; Nieto J; Paterson ME; Tidy J; Duncan A; Chan S; Williamson KM; Weekes A; Adeyemi OA; Henry R; Laurence V; Dean S; Poole D; Lind MJ; Dealey R; Godfrey K; Hatem MM; Lopes A; Monaghan JM; Naik R; Evans J; Gillespie A; Paterson ME; Tidy J; Ind T; Lane J; Oates S; Redford D; Ford M; Fish A; Larsen-Disney P; Johnson N; Bolger A; Keating P; Martin-Hirsch P; Richardson L; Murdoch JB; Jeyarajah A; Lamb M; McWhinney N; Farthing A; Mason PW; Kitchener H; Beynon JL; Hogston P; Low EM; Woolas R; Anderson R; Murdoch JB; Niven PA; Kerr-Wilson R; Chin K; Flynn P; Freites O; Newman GH; McNally O; Cullimore J; Olaitan A; Mould T; Menon V; Redman CW; George M; Hatem MH; Evans A; Fiander A; Howells R; Lim K; Cawdell G; Warwick AP; Eustace D; Giles J; Leeson S; Nevin J; van Wijk AL; Karolewski K; Klimek M; Blecharz P; McConnell D
  •  go-up   go-down


22. Kober L, Rustom R, Wiedmann J, Kappelgaard AM, El Nahas M, Feldt-Rasmussen B: Cardiovascular effects of growth hormone in adult hemodialysis patients: results from a randomized controlled trial. Nephron Clin Pract; 2010;115(3):c213-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular effects of growth hormone in adult hemodialysis patients: results from a randomized controlled trial.
  • BACKGROUND/AIMS: The high morbidity and mortality rates in hemodialysis (HD) patients are due, at least in part, to their increased risk for cardiovascular diseases (CVD).
  • This prospective study evaluated the effect of growth hormone (GH) on a number of CVD risk markers in adult patients on HD.
  • METHODS: 139 HD patients were randomized to one of three GH doses or to placebo.
  • CONCLUSION: In adult HD patients, GH treatment had a predominantly beneficial effect on CVD risk markers.
  • [MeSH-minor] Adult. Aged. Biomarkers / blood. Female. Homocysteine / blood. Humans. Male. Middle Aged. Prospective Studies. Risk Factors. Serum Albumin / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20413999.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Serum Albumin; 0LVT1QZ0BA / Homocysteine; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


23. Yabroff KR, Kim Y: Time costs associated with informal caregiving for cancer survivors. Cancer; 2009 Sep 15;115(18 Suppl):4362-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Data from a national survey of caregivers of cancer patients in 2003 to 2006 were used to estimate the time associated with informal caregiving in the 2 years after patient diagnosis with bladder, breast, colorectal, kidney, lung, melanoma of the skin, ovarian, prostate, or uterine cancer, or non-Hodgkins lymphoma (NHL).
  • The number of months and daily hours spent caregiving were the highest for cancer survivors diagnosed with distant disease compared with survivors with regional or localized disease (P<.05).
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Spouses

  • MedlinePlus Health Information. consumer health - Caregivers.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19731345.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Chen F, Winston JH 3rd, Jain SK, Frankel WL: Hirschsprung's disease in a young adult: report of a case and review of the literature. Ann Diagn Pathol; 2006 Dec;10(6):347-51
Genetic Alliance. consumer health - Hirschsprung's disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hirschsprung's disease in a young adult: report of a case and review of the literature.
  • Hirschsprung's disease (HD) in adults is rare and often undiagnosed or misdiagnosed.
  • We report a case of HD in a 26-year-old woman who had a history of chronic constipation that required laxatives and enemas since early childhood.
  • A rectal biopsy showed hypoganglionic anorectum, suspicious for HD.
  • A diagnosis of adult HD was made.
  • Hirschsprung's disease should be considered in adults who have long-standing and refractory constipation.
  • [MeSH-major] Hirschsprung Disease / pathology
  • [MeSH-minor] Adult. Chronic Disease. Constipation / complications. Constipation / pathology. Female. Humans. Proctocolectomy, Restorative. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126253.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Toba H, Kondo K, Yoshida M, Kenzaki K, Miyoshi T, Sakiyama S, Tangoku A: [Clinical experience with 16 cases of mediastinal lymphoma]. Kyobu Geka; 2008 Feb;61(2):97-101
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical experience with 16 cases of mediastinal lymphoma].
  • Sixteen cases of mediastinal lymphoma in our hospital were reviewed clinically.
  • The histological types were non-Hodgkins' disease in 12 (B-cell type in 6 and T-cell type in 6), Hodgkins' disease in 2, mucosa-associated lymphoid tissue (MALT) lymphoma in 2.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / therapy. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Salvage Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268943.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Tsouchnikas I, Tsilipakou M, Daniilidis M, Kyriazis G, Pasadakis P, Parapanissiou E, Vargemezis V, Tsakiris D: Effect of iron loading on peripheral blood lymphocyte subsets and on circulating cytokine levels in iron-depleted hemodialysis patients receiving erythropoietin. Nephron Clin Pract; 2007;107(3):c97-102
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: High doses of iron are recommended intravenously in iron-depleted hemodialysis (HD) patients receiving recombinant erythropoietin (EPO).
  • The aim of this study was to evaluate the effect of iron load on peripheral blood lymphocytes subsets and on circulating cytokine levels in HD iron depleted patients, treated with EPO.
  • METHODS: We studied 19 stable adult HD patients, 12 males, with a mean age 59 +/- 11 years and mean HD duration 24 +/- 14 months.
  • The administered dose of iron was infused intravenously (1,000 mg iron sucrose) in 10 doses, during 10 consecutive HD sessions.
  • Patients were screened before the commencement of the HD session on two occasions, once prior to the first dose of iron and 2 days after the 10th dose.
  • CONCLUSION: Iron load in iron-deficient EPO-treated HD patients did not produce any changes in major lymphocyte subsets in peripheral blood, but it resulted in a significant increase of NKR+ T cells, a subpopulation important for local immune responses.
  • Iron load for a relatively short period improved anemia of HD patients and influenced the levels of the circulating IL-2, which may regulate factors affecting the survival of patients.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Iron.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17890877.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cytokines; 11096-26-7 / Erythropoietin; E1UOL152H7 / Iron
  •  go-up   go-down


27. Clarke CA, Glaser SL, Keegan TH, Stroup A: Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev; 2005 Jun;14(6):1441-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California.
  • Hodgkin's lymphoma occurrence has long been noted to associate with higher socioeconomic status (SES).
  • However, the Hodgkin's lymphoma-SES association has not been examined recently or across important, possibly etiologically distinct, patient subgroups.
  • In approximately 150 million person-years of observation in the multiethnic population of California, we examined the association of Hodgkin's lymphoma incidence with a composite measure of neighborhood-level SES in patient subgroups defined by age, sex, race/ethnicity, and Hodgkin's lymphoma histologic subtype.
  • Using population-based cancer registry data on 3,794 Hodgkin's lymphoma patients diagnosed 1988 to 1992 and 1990 census data, we assigned a previously validated, multidimensional SES index to census block groups of patient residence.
  • Positive neighborhood SES gradients in Hodgkin's lymphoma incidence were observed only in young adults (ages 15-44 years at diagnosis) with nodular sclerosis Hodgkin's lymphoma and older adult (ages > or =45 years) White and Hispanic males with mixed cellularity Hodgkin's lymphoma.
  • For young adults, associations were marked in Hispanic and Asian women, weaker in Hispanic and White men and White women, and subtle to nonexistent in Blacks and Asian men.
  • Neighborhood SES gradients in Hodgkin's lymphoma incidence varied by age, sex, race/ethnicity, and histologic subtype, underscoring etiologic complexity in Hodgkin's lymphoma.
  • In California, etiologically relevant exposures for young adult Hodgkin's lymphoma, the most common form, could associate more with race/ethnicity or foreign birthplace than neighborhood SES and may be modified by reproductive or other sex-specific factors.
  • [MeSH-major] Hodgkin Disease / economics. Hodgkin Disease / epidemiology. Registries / statistics & numerical data. Social Class
  • [MeSH-minor] Adolescent. Adult. Aged. California / epidemiology. Child. Child, Preschool. Continental Population Groups. Ethnic Groups. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Residence Characteristics. Risk Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941953.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB: Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol; 2010 Jun;5(6):1010-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
  • BACKGROUND AND OBJECTIVES: Hepcidin, the principal regulator of iron homeostasis, may play a critical role in the response of patients with anemia to iron and erythropoiesis-stimulating agent therapy; however, the contribution of hepcidin to iron maldistribution and anemia in hemodialysis (HD) patients and the ability of HD to lower serum hepcidin levels have not been fully characterized.
  • DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured serum hepcidin using a competitive ELISA in 30 pediatric and 33 adult HD patients.
  • In addition, we determined serum hepcidin kinetics and calculated hepcidin clearance by measuring serum hepcidin before, during, and after HD in eight pediatric and six adult patients.
  • RESULTS: Hepcidin was significantly increased in pediatric (median 240.5 ng/ml) and adult HD patients (690.2 ng/ml) when compared with their respective control subjects (pediatric 25.3 ng/ml, adult 72.9 ng/ml).
  • Multivariate regression analysis showed that serum hepcidin was independently predicted by ferritin and high-sensitivity C-reactive protein in the pediatric group and ferritin, percentage of iron saturation, and high-sensitivity C-reactive protein in the adult group.
  • Hepcidin clearance by HD was 141 +/- 40 and 128 +/- 44 ml/min in pediatric and adult patients, respectively (NS).
  • CONCLUSIONS: These findings suggest that hepcidin may mediate the negative effects of inflammation on both disordered iron metabolism and erythropoiesis in HD patients and that intensification of HD could be used therapeutically to reduce hepcidin concentrations and thereby improve erythropoiesis-stimulating agent responsiveness.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2002 Oct;110(7):1037-44 [12370282.001]
  • [Cites] Nephrol Dial Transplant. 2010 Mar;25(3):848-53 [19854845.001]
  • [Cites] Am J Kidney Dis. 2003 Nov;42(5):1020-35 [14582046.001]
  • [Cites] J Clin Invest. 2004 May;113(9):1271-6 [15124018.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2090-3 [15514116.001]
  • [Cites] Clin Nephrol. 2005 Mar;63(3):202-8 [15786821.001]
  • [Cites] Blood. 2005 May 15;105(10):4103-5 [15671438.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1864-6 [15886319.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1381-7 [16621968.001]
  • [Cites] Physiol Res. 2006;55(6):667-74 [16497104.001]
  • [Cites] Am J Nephrol. 2008;28(1):115-21 [17943020.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4292-7 [18689548.001]
  • [Cites] Kidney Int. 2009 May;75(9):976-81 [19212416.001]
  • [Cites] Clin J Am Soc Nephrol. 2009 Jun;4(6):1051-6 [19406957.001]
  • [Cites] Eur J Clin Invest. 2009 Oct;39(10):883-90 [19563467.001]
  • [Cites] J Proteomics. 2010 Jan 3;73(3):527-36 [19683083.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2461-3 [12433676.001]
  • (PMID = 20299375.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 5R01DK067563-04; United States / NIDDK NIH HHS / DK / R01 DK067563; United States / NIDDK NIH HHS / DK / R01 DK065029; United States / NIDDK NIH HHS / DK / 1K08DK074284-01; United States / NIDDK NIH HHS / DK / K08 DK074284
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Biomarkers; 0 / HAMP protein, human; 0 / Hematinics; 0 / Hepcidins; 0 / Inflammation Mediators; 9007-41-4 / C-Reactive Protein; 9007-73-2 / Ferritins; E1UOL152H7 / Iron
  • [Other-IDs] NLM/ PMC2879302
  •  go-up   go-down


29. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Hodgkins D, Goldsmith K, Hughes RJ, Sheares K, Tsui SS, Armstrong IJ, Torpy C, Crackett R, Carlin CM, Das C, Coghlan JG, Pepke-Zaba J: Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med; 2008 May 15;177(10):1122-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RATIONALE: The management of chronic thromboembolic pulmonary hypertension (CTEPH) has changed over recent years with the growth of pulmonary endarterectomy surgery and the availability of disease-modifying therapies.
  • MEASUREMENTS AND MAIN RESULTS: A total of 469 patients received a diagnosis, of whom 148 (32%) had distal, nonsurgical disease.
  • One- and three-year survival from diagnosis was 82 and 70% for patients with nonsurgical disease and 88 and 76% for those treated surgically (P = 0.023).
  • Initial functional improvement in patients with nonsurgical disease was noted but did not persist at 2 years.
  • CONCLUSIONS: The prognosis in nonsurgical disease has improved.
  • We have confirmed the previously described good outcome in surgically treated disease.
  • [MeSH-minor] Adult. Aged. Chronic Disease. Cohort Studies. Exercise Test. Exercise Tolerance / drug effects. Female. Great Britain / epidemiology. Humans. Male. Middle Aged. Pulmonary Artery / pathology. Pulmonary Artery / surgery. Pulmonary Circulation. Retrospective Studies. Survival Analysis. Thromboembolism / complications. Thromboembolism / mortality. Treatment Outcome

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18292468.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105232027
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Platelet Aggregation Inhibitors
  •  go-up   go-down


30. Musacchio JG, Carvalho Mda G, Morais JC, Silva NH, Scheliga A, Romano S, Spector N: Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin's disease. Sao Paulo Med J; 2006 May 4;124(3):154-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin's disease.
  • CONTEXT AND OBJECTIVE: Free circulating Epstein-Barr virus (EBV) DNA is often present in the plasma of Hodgkins disease patients.
  • DESIGN AND SETTING: Prospective study in two public tertiary institutions: Hematology Service, Universidade Federal do Rio de Janeiro, and Oncology Service, Instituto Nacional do Câncer, Rio de Janeiro.
  • METHODS: A cohort of 30 patients with newly diagnosed Hodgkins disease was studied.
  • The control group consisted of 13 healthy adult volunteers.
  • Advanced disease was present in 19 patients, and six were HIV-positive.
  • EBV DNA prevalence was higher in HIV-positive patients (100% versus 29%, p = 0.0007) and those with advanced disease (63% versus 9%, p = 0.006).
  • Among HIV-negative patients alone, EBV DNA prevalence remained higher in those with advanced disease.
  • CONCLUSION: EBV DNA was present in 91% of patients with EBV-associated Hodgkins disease, and in all patients with HIV-associated Hodgkins disease.
  • EBV DNA prevalence was higher in patients with advanced disease, irrespective of HIV status.
  • [MeSH-major] DNA, Viral / blood. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / genetics. Hodgkin Disease / virology
  • [MeSH-minor] Adolescent. Adult. Biomarkers / blood. Case-Control Studies. Chi-Square Distribution. Child. Female. HIV Infections / blood. HIV Infections / virology. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Prospective Studies. Viral Load. Viral Matrix Proteins / blood

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119693.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


31. Wilson KS, Gallagher A, Freeland JM, Shield LA, Jarrett RF: Viruses and Hodgkin lymphoma: no evidence of polyomavirus genomes in tumor biopsies. Leuk Lymphoma; 2006 Jul;47(7):1315-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viruses and Hodgkin lymphoma: no evidence of polyomavirus genomes in tumor biopsies.
  • The epidemiology of young adult Hodgkin lymphoma (HL) suggests that delayed exposure to a common childhood pathogen may be involved in disease pathogenesis.
  • The Epstein-Barr virus (EBV) is associated with a proportion of cases but cases of young adult HL in westernized countries are less frequently EBV-associated than cases in other age groups and geographical locales.
  • [MeSH-major] Genome, Viral. Hodgkin Disease / virology. Polyomavirus / genetics
  • [MeSH-minor] Adult. Aged. Biopsy. DNA Primers / chemistry. Female. Herpesvirus 4, Human / genetics. Humans. Lymph Nodes / pathology. Male. Middle Aged. Molecular Sequence Data. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923562.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY911513
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


32. Hemminki K, Chen B: Familial association of prostate cancer with other cancers in the Swedish Family-Cancer Database. Prostate; 2005 Oct 1;65(2):188-94
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: SIRs for prostate cancer were increased in sons when mothers were diagnosed with breast and ovarian cancers, and when siblings were diagnosed with Hodgkins disease (1.78, N = 18, 95% CI 1.05-2.82) and leukemia (1.39, 43, 1.01-1.88).
  • [MeSH-major] Genetic Predisposition to Disease. Prostatic Neoplasms / genetics. Registries / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Genetic Counseling. Humans. Incidence. Infant. Infant, Newborn. Inheritance Patterns. Male. Middle Aged. Neoplasms / epidemiology. Neoplasms / genetics. Pedigree. Sweden / epidemiology

  • Genetic Alliance. consumer health - Familial Prostate Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15948149.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR: Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neurosci; 2006;7:80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
  • BACKGROUND: Huntington disease (HD) is an adult onset neurodegenerative disorder caused by a polyglutamine expansion in the huntingtin (htt) protein.
  • To determine whether treatment with wild-type htt would be beneficial in HD, we crossed the YAC128 mouse model of HD with mice that over-express wild-type htt (YAC18 mice) to generate YAC128 mice that over-express wild-type htt (YAC18/128 mice).
  • CONCLUSION: While the over-expression of wild-type htt results in a mild improvement in striatal neuropathology in YAC128 mice, our findings suggest that treatment with wild-type htt may not be sufficient to ameliorate the symptoms of HD in this model.
  • [MeSH-major] Huntington Disease / metabolism. Motor Skills / physiology. Neostriatum / pathology. Nerve Tissue Proteins / metabolism. Neurons / pathology. Nuclear Proteins / metabolism
  • [MeSH-minor] Analysis of Variance. Animals. Atrophy / metabolism. Cell Count. Cell Size. Disease Models, Animal. Dopamine and cAMP-Regulated Phosphoprotein 32 / metabolism. Mice. Mice, Neurologic Mutants. Mice, Transgenic. Rotarod Performance Test

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Mar 1;9(4):503-13 [10699173.001]
  • [Cites] EMBO J. 2006 Dec 13;25(24):5896-906 [17124493.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):300-6 [11062468.001]
  • [Cites] J Biol Chem. 2000 Dec 29;275(52):41299-308 [11007801.001]
  • [Cites] Hum Mol Genet. 2001 Jan 15;10(2):137-44 [11152661.001]
  • [Cites] Am J Hum Genet. 2001 Feb;68(2):313-24 [11133364.001]
  • [Cites] Trends Neurosci. 2001 Mar;24(3):182-8 [11182459.001]
  • [Cites] J Med Genet. 2001 Jul;38(7):450-2 [11432963.001]
  • [Cites] Science. 2001 Jul 20;293(5529):493-8 [11408619.001]
  • [Cites] Hum Mol Genet. 2001 Oct 15;10(22):2515-23 [11709539.001]
  • [Cites] Brain. 2003 Apr;126(Pt 4):946-55 [12615650.001]
  • [Cites] Hum Mol Genet. 2003 Jul 1;12(13):1555-67 [12812983.001]
  • [Cites] Nat Genet. 2003 Sep;35(1):76-83 [12881722.001]
  • [Cites] J Neurosci. 2003 Oct 15;23(28):9418-27 [14561870.001]
  • [Cites] Trends Genet. 2004 Mar;20(3):146-54 [15036808.001]
  • [Cites] Cell. 2004 Jul 9;118(1):127-38 [15242649.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1310-7 [15336977.001]
  • [Cites] Nature. 1987 Mar 12-18;326(6109):194-7 [2881213.001]
  • [Cites] Am J Hum Genet. 1989 Oct;45(4):615-8 [2535231.001]
  • [Cites] N Engl J Med. 1994 May 19;330(20):1401-6 [8159192.001]
  • [Cites] Cell. 1995 Jun 2;81(5):811-23 [7774020.001]
  • [Cites] Science. 1995 Jul 21;269(5222):407-10 [7618107.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):155-63 [7550343.001]
  • [Cites] J Biol Chem. 1996 Aug 9;271(32):19385-94 [8702625.001]
  • [Cites] Hum Mol Genet. 1996 Dec;5(12):1875-85 [8968738.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):404-10 [9398841.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):198-202 [9771716.001]
  • [Cites] Ann Neurol. 1999 Jan;45(1):25-32 [9894873.001]
  • [Cites] J Med Genet. 1999 Feb;36(2):172-3 [10051023.001]
  • [Cites] Brain Res. 1999 Feb 13;818(2):468-79 [10082833.001]
  • [Cites] Neuron. 1999 May;23(1):181-92 [10402204.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8727-32 [10411943.001]
  • [Cites] Neurology. 1999 Sep 11;53(4):801-6 [10489044.001]
  • [Cites] J Neurosci. 2004 Nov 17;24(46):10335-42 [15548647.001]
  • [Cites] J Biol Chem. 2005 Jan 7;280(1):556-63 [15494404.001]
  • [Cites] J Neurosci. 2005 Apr 20;25(16):4169-80 [15843620.001]
  • [Cites] Hum Mol Genet. 2005 May 15;14(10):1379-92 [15829505.001]
  • [Cites] Exp Neurol. 2005 Dec;196(2):266-72 [16129433.001]
  • [Cites] Neurobiol Dis. 2006 Feb;21(2):444-55 [16230019.001]
  • [Cites] J Neurochem. 2006 Feb;96(4):1121-9 [16417581.001]
  • [Cites] Hum Mol Genet. 2006 May 1;15(9):1513-23 [16571604.001]
  • [Cites] J Neurosci. 2000 May 15;20(10):3705-13 [10804212.001]
  • (PMID = 17147801.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine and cAMP-Regulated Phosphoprotein 32; 0 / Huntington protein, mouse; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / Ppp1r1b protein, mouse
  • [Other-IDs] NLM/ PMC1762017
  •  go-up   go-down


34. Nguyen HP, Metzger S, Holzmann C, Koczan D, Thiesen HJ, von Hörsten S, Riess O, Bonin M: Age-dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease. Proteomics Clin Appl; 2008 Dec;2(12):1638-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease.
  • Polyglutamine-induced changes in gene expression have been demonstrated by using several mouse models of Huntington's disease (HD), which express extreme numbers of CAG repeats.
  • We have recently developed a transgenic rat model of HD carrying a truncated huntingtin fragment with 51 CAG repeats, which is in the range seen in adult HD patients.
  • A detailed analysis of canonical pathways revealed that at 3 months of age genes in calcium signaling and synaptic long term potentation pathways were altered, while at 12 months of age, additionally, expression level of many genes implicated in Huntington's disease signaling, were changed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 21136814.001).
  • [ISSN] 1862-8346
  • [Journal-full-title] Proteomics. Clinical applications
  • [ISO-abbreviation] Proteomics Clin Appl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Bortvedt SF, McLear JA, Messer A, Ahern-Rindell AJ, Wolfgang WJ: Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease. Neurobiol Dis; 2010 Oct;40(1):130-4
FlyBase. FlyBase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.
  • Huntington's disease (HD) is a lethal, neurodegenerative disorder caused by expansion of the polyglutamine repeat in the Huntingtin gene (HTT), leading to mutant protein misfolding, aggregation, and neuronal death.
  • Feeding a Drosophila HD model cystamine, or expressing a transgene encoding the anti-htt intracellular antibody (intrabody) C4-scFv in the nervous system, demonstrated therapeutic potential, but suppression of pathology was incomplete.
  • We hypothesized that a combinatorial approach entailing drug and intrabody administration could enhance rescue of HD pathology in flies and that timing of treatment would affect outcomes.
  • Feeding cystamine to adult HD flies expressing the intrabody resulted in a significant, additional rescue of photoreceptor neurodegeneration, but no additional benefit in longevity.
  • Feeding cystamine during both larval and adult stages produced the converse result: longevity was significantly improved, but increased photoreceptor survival was not.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Inc. All rights reserved.
  • [Cites] Curr Opin Mol Ther. 2006 Feb;8(1):17-23 [16506521.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4246-51 [16537516.001]
  • [Cites] Science. 2000 Mar 10;287(5459):1837-40 [10710314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4764-9 [11296304.001]
  • [Cites] Nature. 2001 Oct 18;413(6857):739-43 [11607033.001]
  • [Cites] Neurosci Lett. 2001 Nov 27;315(3):149-53 [11716985.001]
  • [Cites] Nat Med. 2002 Feb;8(2):143-9 [11821898.001]
  • [Cites] J Neurosci. 2002 Oct 15;22(20):8942-50 [12388601.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3825-30 [12458211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5950-5 [12730384.001]
  • [Cites] Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R187-93 [12925571.001]
  • [Cites] Nat Med. 2004 Jul;10 Suppl:S10-7 [15272267.001]
  • [Cites] J Neurochem. 2004 Oct;91(2):413-22 [15447674.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):805-10 [15483602.001]
  • [Cites] Mol Cell Biochem. 1984;58(1-2):9-35 [6143256.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7388-93 [10377424.001]
  • [Cites] J Neurochem. 2005 Jan;92(1):83-92 [15606898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3777-81 [15716359.001]
  • [Cites] Eur J Neurosci. 2005 Feb;21(4):855-70 [15787692.001]
  • [Cites] Neurobiol Dis. 2005 Jun-Jul;19(1-2):47-56 [15837560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5820-5 [15811941.001]
  • [Cites] Mol Ther. 2005 Sep;12(3):394-401 [15964243.001]
  • [Cites] J Neurochem. 2005 Oct;95(1):210-20 [16181425.001]
  • [Cites] Biochim Biophys Acta. 2006 Mar;1762(3):373-80 [16364609.001]
  • [Cites] Mov Disord. 2006 Apr;21(4):530-3 [16258942.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1410-24 [16604191.001]
  • [Cites] Neuroscience. 2006 Sep 15;141(4):1835-48 [16809003.001]
  • [Cites] Neuron. 2006 Oct 5;52(1):169-78 [17015234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11563-8 [16061794.001]
  • [Cites] Hum Mol Genet. 2008 Jan 15;17(2):170-8 [17921520.001]
  • [Cites] FASEB J. 2008 Jun;22(6):2003-11 [18199697.001]
  • [Cites] J Cell Biol. 2008 Jun 2;181(5):803-16 [18504298.001]
  • [Cites] FEBS J. 2008 Sep;275(17):4252-62 [18637947.001]
  • [Cites] J Neurochem. 2009 Jun;109(5):1427-39 [19476553.001]
  • [Cites] Expert Opin Biol Ther. 2009 Sep;9(9):1189-97 [19653865.001]
  • [Cites] J Neurosci. 2009 Oct 28;29(43):13589-602 [19864571.001]
  • [Cites] Nat Struct Mol Biol. 2009 Dec;16(12):1279-85 [19915590.001]
  • [Cites] J Cell Biol. 2009 Dec 28;187(7):1083-99 [20026656.001]
  • [Cites] Neuron. 2009 Dec 24;64(6):828-40 [20064390.001]
  • [Cites] J Mol Biol. 2010 Mar 12;396(5):1295-309 [20026071.001]
  • (PMID = 20399860.001).
  • [ISSN] 1095-953X
  • [Journal-full-title] Neurobiology of disease
  • [ISO-abbreviation] Neurobiol. Dis.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS053912; United States / NINDS NIH HHS / NS / NS053912
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; R110LV8L02 / Cystamine
  • [Other-IDs] NLM/ NIHMS199601; NLM/ PMC2924926
  •  go-up   go-down


36. Furth C, Steffen IG, Amthauer H, Ruf J, Misch D, Schönberger S, Kobe C, Denecke T, Stöver B, Hautzel H, Henze G, Hundsdoerfer P: Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol; 2009 Sep 10;27(26):4385-91
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial.
  • PURPOSE: In adult Hodgkin's lymphoma (HL) risk stratification after early therapy response assessment with [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) seems to allow tailoring therapy with less toxicity for patients with adequate metabolic response.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radionuclide imaging. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667276.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


37. Iseh KR, Abdullahi A, Malami SA: Clinical and histological characteristics of nasopharyngeal cancer in Sokoto, north-western, Nigeria. West Afr J Med; 2009 May;28(3):151-5
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cancer of the nasopharynx poses diagnostic and therapeutic difficulties because of the hidden nature of the nasopharyngeal space, which allows for significant spread of the disease before diagnosis and hence poor prognosis.
  • The histological diagnoses were squamous cell carcinoma 23 (76.7%) cases, non-Hodgkins lymphoma 3 (10%) cases, plasmacytoma 2 (6.7%) cases, rhabdomyosarcoma one (3.3%) case, karposis sarcoma one (3.3%) cases.
  • CONCLUSION: Nasopharyngeal cancer in Northern Nigeria is characterised by presentation with advanced disease, high mortality and low 5-year survival rates.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Combined Modality Therapy. Female. Hospitals, Teaching. Humans. Lymphatic Metastasis / pathology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Nigeria. Plasmacytoma / pathology. Prognosis. Sex Distribution. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306729.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


38. Corti M, Solari R, Cangelosi D, De Carolis L, Schtirbu R, Lewi D: Oral cavity lymphoma as secondary AIDS-defining neoplasm in a patient on HAART with immune reconstitution. Rev Soc Bras Med Trop; 2007 Sep-Oct;40(5):582-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral cavity lymphoma as secondary AIDS-defining neoplasm in a patient on HAART with immune reconstitution.
  • Lymphomas of the oral cavity are a rare complication of advanced HIV/AIDS disease.
  • We report the case of a patient with AIDS who developed diffuse large B-cell non-Hodgkins lymphoma of the oral cavity during highly active antiretroviral therapy, with undetectable plasma viral load and immune reconstitution.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cyclophosphamide. Doxorubicin. Humans. Male. Prednisone. Vincristine


39. Marsenic O, Zhang L, Zuppa A, Barrett JS, Pfister M: Application of Individualized Bayesian Urea Kinetic Modeling to pediatric hemodialysis. ASAIO J; 2010 May-Jun;56(3):246-53
Hazardous Substances Data Bank. UREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incorporating urea rebound using equilibrated urea concentration (Ceq) after hemodialysis (HD) is essential for accurate assessment of HD efficiency.
  • The objective of this work is to assess the ability of an Individualized Bayesian Urea Kinetic Model (IBKM) for predicting Ceq in children receiving HD.
  • Developed based on adult HD data, the IBKM is a two-pool urea kinetic model that calculates Bayesian estimates of individual Ceq.
  • Blood urea nitrogen (BUN) samples from 30 HD sessions in 13 children (age 12-18 years) were taken at pre-HD, immediately post-HD, and 60 minutes post-HD (Ceq).
  • The IBKM and estimated population parameters from adult data were fitted to the observed data from children to predict individual Ceq using NONMEM VI software in comparison with observed Ceq (9.5 +/- 3.8 mmol/L), the average individual predicted Ceq was 9.4 +/- 3.8 mmol/L, with absolute individual prediction error of 6.2% +/- 4.4%.
  • This study suggests that the IBKM can be used in a pediatric HD setting and accurately predict Ceq in children using only pre-HD and immediately post-HD BUN.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168209.001).
  • [ISSN] 1538-943X
  • [Journal-full-title] ASAIO journal (American Society for Artificial Internal Organs : 1992)
  • [ISO-abbreviation] ASAIO J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8W8T17847W / Urea
  •  go-up   go-down


40. Kuo HL, Chou CY, Liu YL, Yang YF, Huang CC, Lin HH: Reduction of pro-inflammatory cytokines through hemodiafiltration. Ren Fail; 2008;30(8):796-800
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hemodialysis (HD) prolongs the life of the patients with end stage renal disease (ESRD), but the survival rates are still lower than the general population.
  • More than half of ESRD patients died from cardiovascular disease (CVD).
  • METHODS: Seventeen adult HD outpatients were put on HDF in our hospital from September 2004 to June 2006.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791954.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-18; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


41. Wang SH, Chu CY, Chen HH, Chang YL, Chen KY, Chiu HC: Paraneoplastic Pemphigus and Bronchiolitis Obliterans in a Patient with Splenic B-cell Lymphoma. J Formos Med Assoc; 2007 Sep;106(9):768-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic Pemphigus and Bronchiolitis Obliterans in a Patient with Splenic B-cell Lymphoma.
  • The common underlying neoplasms include non-Hodgkins lymphoma, chronic lymphocytic leukemia, and Castlemans disease.
  • Though B-cell lymphoma is the most common underlying malignancy, only one case associated with splenic B-cell lymphoma has been recognized.
  • Serial workup established the diagnosis of PNP and revealed an underlying splenic B-cell lymphoma.

  • Genetic Alliance. consumer health - Pemphigus.
  • Genetic Alliance. consumer health - Bronchiolitis Obliterans.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908666.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


42. Hou HA, Tang JL, Hsu SC, Yu CL, Chen YC, Yao M: Acquisition and cure of autoimmune disease following allogeneic hematopoietic stem cell transplantation. J Formos Med Assoc; 2007 Sep;106(9):779-83
MedlinePlus Health Information. consumer health - Autoimmune Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquisition and cure of autoimmune disease following allogeneic hematopoietic stem cell transplantation.
  • Hematopoietic stem cell transplantation (HSCT) can either cause or eliminate autoimmune disease.
  • One was a 33-year-old woman with myelodysplastic syndrome (refractory anemia) who received bone marrow transplantation from her human leukocyte antigen (HLA)-identical sister who had a history of Graves disease.
  • The other case was a 50-year-old woman with Sjgrens syndrome and hypothyroidism who was diagnosed with peripheral T cell non-Hodgkins lymphoma.
  • Cure of lymphoma and remission of Sjgrens syndrome was noted 4 years after PBSCT.
  • These two illustrative cases, one of acquisition of hyperthyroidism and the other of remission of Sjgrens syndrome after transplantation, highlights that HSCT can induce adoptive autoimmune disease or cure coincidental autoimmune disease.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908668.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Autoantibodies
  •  go-up   go-down


43. Tang Y, Wang Y, Yang P, Liu Y, Wang B, Podolsky R, McIndoe R, Wang CY: Intergeneration CAG expansion and contraction in a Chinese HD family. Am J Med Genet B Neuropsychiatr Genet; 2006 Apr 5;141B(3):242-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intergeneration CAG expansion and contraction in a Chinese HD family.
  • The prevalence of juvenile-onset Huntington's disease (HD) is about ten times lower than adult HD.
  • Here we report a Chinese HD family showing both intergeneration CAG expansion and contraction.
  • The expansion resulted from a paternal transmission which leads to juvenile-onset HD for a 17-year-old Chinese boy (III-5).
  • More interestingly, a contraction was noticed in a maternal transmission (III-3), which changed the CAG repeat from an expanded, disease-causing allele (48 repeats) to a normal or intermediate allele (34 repeats).
  • Our results are consistent with previous observations in Western Caucasians that juvenile-onset HD is more likely inherited through the male germline.
  • [MeSH-major] Huntington Disease / genetics. Nerve Tissue Proteins / genetics. Nuclear Proteins / genetics. Trinucleotide Repeat Expansion / genetics. Trinucleotide Repeats / genetics
  • [MeSH-minor] Adolescent. Adult. Alleles. China. Family Health. Female. Genotype. Humans. Inheritance Patterns. Male. Middle Aged. Pedigree. Polymorphism, Single Nucleotide. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16526033.001).
  • [ISSN] 1552-4841
  • [Journal-full-title] American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • [ISO-abbreviation] Am. J. Med. Genet. B Neuropsychiatr. Genet.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 143100
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


44. Negri E: Sun exposure, vitamin D, and risk of Hodgkin and non-Hodgkin lymphoma. Nutr Cancer; 2010;62(7):878-82
MedlinePlus Health Information. consumer health - Vitamin D.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sun exposure, vitamin D, and risk of Hodgkin and non-Hodgkin lymphoma.
  • Similarities in the epidemiology of melanoma, other skin cancers, and non-Hodgkin lymphoma (NHL) have led to the hypothesis that UV exposure, the major risk factor for cutaneous cancers, could play a role on NHL risk too.
  • The paucity of information on the relation of sun exposure or vitamin D with adult Hodgkin lymphoma (HL) or childhood lymphomas prevents any definite conclusion.
  • [MeSH-major] Lymphoma, Non-Hodgkin / etiology. Sunlight / adverse effects. Vitamin D / analogs & derivatives
  • [MeSH-minor] Disease Susceptibility. Humans. Risk Factors. SEER Program

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924963.001).
  • [ISSN] 1532-7914
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; 64719-49-9 / 25-hydroxyvitamin D
  •  go-up   go-down


45. Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersén A, Björkqvist M, Muir C, Mackenzie IR, Hammond GL, Vogl AW, Hayden MR, Leavitt BR: Testicular degeneration in Huntington disease. Neurobiol Dis; 2007 Jun;26(3):512-20
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular degeneration in Huntington disease.
  • Huntington disease (HD) is an adult onset, neurodegenerative disorder that results from CAG expansion in the HD gene.
  • Recent work has demonstrated testicular degeneration in mouse models of HD and alterations in the hypothalamic-pituitary-gonadal (HPG) axis in HD patients.
  • Here, we show that HD patients have specific testicular pathology with reduced numbers of germ cells and abnormal seminiferous tubule morphology.
  • Understanding the pathogenesis of HD in the testis may reveal common critical pathways which lead to degeneration in both the brain and testis.
  • [MeSH-major] Huntington Disease / complications. Huntington Disease / physiopathology. Nerve Tissue Proteins / metabolism. Nuclear Proteins / metabolism. Testicular Diseases / etiology. Testicular Diseases / physiopathology. Testis / physiopathology
  • [MeSH-minor] Adult. Aged. Animals. Disease Models, Animal. Germ Cells / metabolism. Germ Cells / pathology. Gonadotropin-Releasing Hormone / metabolism. Gonadotropin-Releasing Hormone / secretion. Humans. Hypothalamo-Hypophyseal System / metabolism. Hypothalamo-Hypophyseal System / physiopathology. Male. Mice. Mice, Transgenic. Middle Aged. Neurons / metabolism. Neurons / pathology. Neurons / secretion. Seminiferous Tubules / metabolism. Seminiferous Tubules / pathology. Seminiferous Tubules / physiopathology. Testosterone / blood


46. Schwartz CL: Special issues in pediatric Hodgkin's disease. Eur J Haematol Suppl; 2005 Jul;(66):55-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Special issues in pediatric Hodgkin's disease.
  • Childhood Hodgkin's disease (HD) is not a biologically unique disease; it differs from adult HD primarily in the relative incidence of disease histology.
  • Preadolescent children are more likely to have Mixed Cellularity and nodular lymphocyte predominant HD.
  • Adolescent and young adult HD is indistinguishable, with a predominance of nodular sclerosing (NS) HD.
  • The latter concerns are of equal relevance to the young adult with HD.
  • Although the dose dense regimens of adult groups are similar, the pediatric algorithms emphasize using the enhanced efficacy to limit cumulative therapy.
  • This review intends to address the special issues of childhood HD, with the intent of further encouraging understanding that will foster convergence of pediatric and adult treatment paradigms.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / standards. Child. Child, Preschool. Combined Modality Therapy / adverse effects. Combined Modality Therapy / standards. Humans. Infant. Infant, Newborn. Radiotherapy / adverse effects. Radiotherapy / standards

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007870.001).
  • [ISSN] 0902-4506
  • [Journal-full-title] European journal of haematology. Supplementum
  • [ISO-abbreviation] Eur J Haematol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 80
  •  go-up   go-down


47. Hodgins M, Millar M, Barry MM: "...it's all the same no matter how much fruit or vegetables or fresh air we get": traveller women's perceptions of illness causation and health inequalities. Soc Sci Med; 2006 Apr;62(8):1978-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-one Traveller women were recruited to the focus groups through community projects or adult education initiatives.
  • Further, they broadly rejected behavioural explanations of the heart disease described in the vignette.
  • [MeSH-major] Disease / etiology. Ethnic Groups. Fruit. Health Status. Population Groups. Vegetables
  • [MeSH-minor] Adult. Culture. Female. Focus Groups. Health Services Accessibility. Humans. Ireland. Life Style. Social Identification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213642.001).
  • [ISSN] 0277-9536
  • [Journal-full-title] Social science & medicine (1982)
  • [ISO-abbreviation] Soc Sci Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR: Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet; 2005 Dec 15;14(24):3823-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
  • Huntington disease (HD) is an adult onset neurodegenerative disorder that predominantly affects the striatum and cortex despite ubiquitous expression of mutant huntingtin (htt).
  • Here we demonstrate that this pattern of selective degeneration is present in the YAC128 mouse model of HD.
  • In contrast, nuclear detection of mutant htt occurs earliest and to the greatest extent in the striatum-the region most affected in HD.
  • In contrast to YAC128 mice, the R6/1 mouse model of HD, which expresses exon 1 of mutant htt, exhibits non-selective, widespread atrophy along with non-selective nuclear detection of mutant htt at 10 months of age.
  • Our findings suggest that selective nuclear localization of mutant htt may contribute to the selective degeneration in HD and that appropriately regulated expression of full-length mutant htt in YAC128 mice results in a pattern of degeneration remarkably similar to human HD.
  • [MeSH-major] Brain / pathology. Cell Nucleus / metabolism. Huntington Disease / genetics. Mutation. Nerve Tissue Proteins / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Animals. Atrophy / genetics. Cerebral Cortex / pathology. Disease Models, Animal. Gene Expression Regulation. Humans. Mice. Mice, Transgenic. Promoter Regions, Genetic

  • Genetic Alliance. consumer health - Huntington disease.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278236.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


49. De Padua M, Kaul S, Sarin R, Kaul S, Das PK: Primary lymphoma of the breast: a clinicopathological study. Indian J Pathol Microbiol; 2007 Oct;50(4):722-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the breast: a clinicopathological study.
  • 3 cases of primary non Hodgkins lymphoma of the breast are described, seen over a period of 2 years among 199 cases of breast malignancies.
  • Application of immunohistochemistry greatly aids in differentiating lymphoma from anaplastic carcinoma, with which it can easily be confused.
  • Primary breast lymphoma is a rare disease with reported incidence of 0.04-0.53% of all breast malignancies in most series.
  • [MeSH-major] Breast Neoplasms / pathology. Hodgkin Disease / complications. Lymphoma / diagnosis. Lymphoma / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Carcinoma / diagnosis. Carcinoma / pathology. Cyclophosphamide. Diagnosis, Differential. Doxorubicin. Female. Humans. Middle Aged. Prednisolone. Vincristine

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306536.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


50. Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F: Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets; 2010 Dec;9(6):791-800
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
  • Huntington's disease (HD) is an adult onset neurodegenerative disease caused by a polyglutamine expansion in the huntingtin protein.
  • Recent work has shown that perturbation of kynurenine pathway (KP) metabolism is a hallmark of HD pathology, and that changes in brain levels of KP metabolites may play a causative role in this disease.
  • Recent studies with HD patient samples and in HD model systems have supported the idea that a shift away from the synthesis of KYNA and towards the formation of 3-HK and QUIN may trigger the neuropathological features observed in HD.
  • This intervention ameliorates disease-relevant phenotypes in HD models.
  • Here we review the work implicating the KP in HD pathology and discuss the potential of KMO as a therapeutic target for this disorder.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20942784.001).
  • [ISSN] 1996-3181
  • [Journal-full-title] CNS & neurological disorders drug targets
  • [ISO-abbreviation] CNS Neurol Disord Drug Targets
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS057715; United Kingdom / Medical Research Council / / G0700090; United States / NINDS NIH HHS / NS / NS057715
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 343-65-7 / Kynurenine; EC 1.14.13.9 / Kynurenine 3-Monooxygenase
  •  go-up   go-down


51. Lawce H, Olson S: FISH testing for deletions of chromosome 6q21 and 6q23 in hematologic neoplastic disorders. J Assoc Genet Technol; 2009;35(4):167-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromosome 6q deletions are also commonly found in lymphoid malignancies such as acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), multiple myeloma (MM), mantle zone lymphoma (MZL), and Waldenström's macroglobulinemia (WM).
  • In adult ALL it indicates a favorable prognosis, but in CLL, B-cell small lymphocytic lymphoma (SLL), WM, and MM it has a poor prognosis.
  • Since the deletion of 6q has prognostic implications and may be used to monitor residual disease, FISH analysis remains a valuable tool in treatment of these disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952391.001).
  • [ISSN] 1523-7834
  • [Journal-full-title] Journal of the Association of Genetic Technologists
  • [ISO-abbreviation] J Assoc Genet Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Cheema BS, Singh MA: Exercise training in patients receiving maintenance hemodialysis: a systematic review of clinical trials. Am J Nephrol; 2005 Jul-Aug;25(4):352-64
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Exercise is not routinely advocated in patients with end-stage renal disease (ESRD) receiving maintenance hemodialysis (HD), compared to best practice in other chronically diseased cohorts.
  • Lack of widespread awareness of the exercise in HD literature may be contributing to these shortcomings of clinical practice.
  • (1) to systematically review trials of exercise training involving adult HD patients;.
  • RESULTS: According to the 29 trials reviewed, HD patients can safely derive a myriad of health-related adaptations from engaging in appropriately structured exercise regimens involving aerobic and/or resistance training.
  • [MeSH-minor] Adaptation, Physiological. Adult. Clinical Trials as Topic. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 16088076.001).
  • [ISSN] 0250-8095
  • [Journal-full-title] American journal of nephrology
  • [ISO-abbreviation] Am. J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 48
  •  go-up   go-down


53. Chavers BM, Solid CA, Gilbertson DT, Collins AJ: Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States. J Am Soc Nephrol; 2007 Mar;18(3):952-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States.
  • Infection-related hospitalization (IH) incidence among US Medicare incident pediatric and adult dialysis and transplant patients within 3 yr of presentation was compared from 1996 to 2001: Hemodialysis (HD) patients (pediatric n = 1469; adult n = 305,323); peritoneal dialysis (PD) patients (pediatric n=982; adult n=27,119), and kidney transplant (KTx) patients (pediatric n=1108; adult n=31,663).
  • Cumulative incidence of IH at 36 mo for incident pediatric patients with ESRD during 1996 to 2001 was 39.9% in HD, 51.2% in PD, and 47.4% in KTx patients (HD or PD versus KTx, P<0.0001).
  • Cumulative incidence for adults was 52.6% in HD, 51.8% in PD, and 39.8% in KTx patients (HD or PD versus KTx, P<0.0001).
  • IH rates per 1000 patient-months were highest for pediatric KTx patients (adjusted rate ratio 1.53 versus HD and 1.90 versus PD, P<0.001 for each) and adult HD patients (adjusted rate ratio 1.20 versus KTx and 1.11 versus PD, P < 0.001 for each).
  • Within the first 36 mo of incidence, IH rates are highest for incident pediatric KTx patients compared with HD and PD patients, in contrast to findings for adult patients with ESRD.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17251389.001).
  • [ISSN] 1046-6673
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / N01-DK-9-2343
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


54. Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A: Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A; 2005 Aug 9;102(32):11563-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.
  • Misfolded neuronal proteins have been identified in a number of neurodegenerative disorders and have been implicated in the pathogenesis of diseases that include Alzheimer's disease, Parkinson's disease, prion-based dementia, Huntington's disease (HD), and other polyglutamine diseases.
  • Although underlying mechanisms remain the subject of ongoing research, it is clear that aberrant processing, protein degradation, and aggregate formation or spurious protein association of the abnormal neuronal proteins may be critical factors in disease progression.
  • We have modified an approach with intracellularly expressed single-chain Fv (sFv) antibodies (intrabodies) that bind with unique HD protein epitopes.
  • In cell and tissue culture models of HD, anti-N-terminal huntingtin intrabodies (C4 sFv) reduce aggregation and cellular toxicity.
  • Here, we present the crucial experiment of intrabody-mediated in vivo suppression of neuropathology, using a Drosophila model of HD.
  • In the presence of the C4 sFv intrabody, the proportion of HD flies surviving to adulthood increases from 23% to 100%, and the mean and maximum lifespan of adult HD flies is significantly prolonged.
  • [MeSH-major] Huntington Disease / pathology. Huntington Disease / therapy. Immunoglobulin Fragments / therapeutic use. Immunotherapy / methods. Lymphokines / immunology. Protein Engineering / methods. Sialoglycoproteins / immunology

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2001 Jan;3(1):113-21 [11162318.001]
  • [Cites] Nature. 2000 Nov 2;408(6808):101-6 [11081516.001]
  • [Cites] Nature. 2001 Oct 18;413(6857):739-43 [11607033.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1002-7 [11792860.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):367-76 [11925563.001]
  • [Cites] Trends Genet. 2002 Apr;18(4):202-9 [11932021.001]
  • [Cites] Trends Genet. 2002 Sep;18(9):463-71 [12175807.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):855-64 [12372281.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41032-7 [12171927.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):373-9 [12540902.001]
  • [Cites] Nat Biotechnol. 2003 Feb;21(2):163-70 [12536217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2041-6 [12576549.001]
  • [Cites] Nat Rev Genet. 2003 Mar;4(3):181-94 [12610523.001]
  • [Cites] Science. 2003 Apr 18;300(5618):486-9 [12702875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5950-5 [12730384.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1253-9 [12761040.001]
  • [Cites] Mol Ther. 2003 Sep;8(3):355-66 [12946308.001]
  • [Cites] Annu Rev Neurosci. 2003;26:627-56 [12704223.001]
  • [Cites] Neuron. 2003 Sep 25;40(1):25-40 [14527431.001]
  • [Cites] Neuron. 2003 Nov 13;40(4):685-94 [14622574.001]
  • [Cites] Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):141-5 [14969746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3224-9 [14978262.001]
  • [Cites] Biochemistry. 2004 Mar 16;43(10):2871-8 [15005622.001]
  • [Cites] Nat Rev Neurosci. 2004 May;5(5):373-84 [15100720.001]
  • [Cites] Bioessays. 2004 May;26(5):485-96 [15112229.001]
  • [Cites] FASEB J. 2004 May;18(7):923-5 [15001566.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):585-95 [15146184.001]
  • [Cites] Hum Mol Genet. 2004 Jul 1;13(13):1389-405 [15115766.001]
  • [Cites] Curr Mol Med. 2004 Aug;4(5):519-28 [15267223.001]
  • [Cites] Nat Med. 2004 Jul;10 Suppl:S2-9 [15272266.001]
  • [Cites] Nat Med. 2004 Jul;10 Suppl:S10-7 [15272267.001]
  • [Cites] J Mol Biol. 2004 Sep 17;342(3):901-12 [15342245.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):805-10 [15483602.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Development. 1993 Jun;118(2):401-15 [8223268.001]
  • [Cites] Cell. 1996 Nov 1;87(3):493-506 [8898202.001]
  • [Cites] Adv Protein Chem. 1996;49:329-450 [8908302.001]
  • [Cites] Cell. 1997 Aug 8;90(3):537-48 [9267033.001]
  • [Cites] Science. 1997 Sep 26;277(5334):1990-3 [9302293.001]
  • [Cites] Neuron. 1998 Sep;21(3):633-42 [9768849.001]
  • [Cites] J Neurosci. 1999 Apr 1;19(7):2522-34 [10087066.001]
  • [Cites] J Exp Biol. 1999 Nov;202(Pt 21):3037-48 [10518485.001]
  • [Cites] Curr Opin Mol Ther. 2004 Oct;6(5):482-90 [15537049.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1023-31 [15564134.001]
  • [Cites] Hum Gene Ther. 2004 Nov;15(11):1131-54 [15610613.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17616-21 [15598740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3777-81 [15716359.001]
  • [Cites] Neurobiol Dis. 2005 Jun-Jul;19(1-2):47-56 [15837560.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):425-8 [10581028.001]
  • [Cites] Hum Mol Genet. 2000 Jan 1;9(1):13-25 [10587574.001]
  • [Cites] Science. 2000 Mar 10;287(5459):1837-40 [10710314.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3081-7 [10955787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4764-9 [11296304.001]
  • (PMID = 16061794.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epitopes; 0 / Fv protein, human; 0 / HTT protein, human; 0 / Immunoglobulin Fragments; 0 / Lymphokines; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / Sialoglycoproteins
  • [Other-IDs] NLM/ PMC1183604
  •  go-up   go-down


55. Self J, Mercer C, Boon EM, Murugavel M, Shawkat F, Hammans S, Hodgkins P, Griffiths H, Lotery A: Infantile nystagmus and late onset ataxia associated with a CACNA1A mutation in the intracellular loop between s4 and s5 of domain 3. Eye (Lond); 2009 Dec;23(12):2251-5
Genetic Alliance. consumer health - Ataxia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Co-segregation of the disease and an identified sequence variation was shown using direct sequencing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19182766.001).
  • [ISSN] 1476-5454
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / / G0501759; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CACNA1A protein, human; 0 / Calcium Channels
  •  go-up   go-down


56. Mileshkin LR, Seymour JF, Wolf MM, Gates P, Januszewicz EH, Joyce P, Prince HM: Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma; 2005 Nov;46(11):1575-9
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-dose therapy (HDT) for non-Hodgkins lymphoma (NHL) and multiple myeloma (MM) is considered a feasible option for patients aged 60 years.
  • Event-free (EFS) and overall survival (OS) rates were compared with a cohort group, matched by disease type, chemotherapy sensitivity, year of treatment and conditioning regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiovascular Diseases / chemically induced. Drug-Related Side Effects and Adverse Reactions. Lymphoma, Non-Hodgkin / complications. Multiple Myeloma / complications. Peripheral Blood Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Age Factors. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236612.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Ding SQ, Chen YT, Ding YJ, Liu F, Ye H: [Diagnosis and surgical management of adult Hirschsprung disease]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jan;9(1):53-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical management of adult Hirschsprung disease].
  • OBJECTIVE: To investigate the diagnosis and surgical treatment of adult Hirschsprung disease (AHD).
  • CONCLUSIONS: The diagnosis of adult HD mainly depends on the history of constipation, barium enema and manometry examination.
  • The pull-through procedures are effective surgical treatments for adult HD.
  • [MeSH-major] Hirschsprung Disease / diagnosis. Hirschsprung Disease / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437373.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


58. Geevasinga N, Richards FH, Jones KJ, Ryan MM: Juvenile Huntington disease. J Paediatr Child Health; 2006 Sep;42(9):552-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile Huntington disease.
  • Huntington disease (HD) is a dominantly inherited neurodegenerative disorder related to expansion of a triplet repeat sequence in the huntington gene on chromosome 4.
  • Adult HD usually presents with chorea and personality changes.
  • Juvenile HD is far less common and presents with parkinsonism, dystonia and seizures.
  • We report a case of juvenile HD, showing extreme anticipation, in which diagnosis was delayed because of failure to recognise the significance of the family history and the characteristic clinical and radiologic features of this condition.
  • [MeSH-major] Diagnostic Errors. Huntington Disease / diagnosis
  • [MeSH-minor] Age of Onset. Child. Disease Progression. Humans. Magnetic Resonance Imaging. Male. Polymorphism, Genetic


59. Higashi M, Ieiri S, Teshiba R, Saeki I, Esumi G, Taguchi T: Hirschsprung's disease patients diagnosed at over 15 years of age: an analysis of a Japanese nationwide survey. Pediatr Surg Int; 2009 Nov;25(11):945-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hirschsprung's disease patients diagnosed at over 15 years of age: an analysis of a Japanese nationwide survey.
  • PURPOSE: Hirschsprung's disease (HD) is usually diagnosed in patients who are under 1 year of age, however, there are still several reports of adult HD cases.
  • We herein analyzed the data of HD patients collected over 30 years according to a nationwide survey in Japan.
  • METHODS: The data of HD patients over 15 years of age were thus selected in three phases, namely from 1978 to 1982, from 1988 to 1992, and from 1998 to 2002.
  • CONCLUSIONS: Twenty-seven HD patients diagnosed over 15 years of age were analyzed.
  • However, further attention is still required in adult patients who are present with persistent intestinal obstruction of unknown etiology.
  • [MeSH-major] Hirschsprung Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Female. Humans. Japan. Male. Middle Aged. Surveys and Questionnaires. Young Adult

  • Genetic Alliance. consumer health - Hirschsprung's disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19690873.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Bilgic A, Ozdemir FN, Bayraktar N, Karakus S, Sasak G, Arat Z, Sezer S, Haberal M: Soluble endothelial protein C receptor: influence on arteriovenous fistula thrombosis development in hemodialysis patients. Am J Nephrol; 2007;27(4):366-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Arteriovenous fistulae (AVF) thrombosis is a common cause of morbidity in hemodialysis (HD) patients.
  • We aimed to investigate the possible effects of sEPCR levels on the development of AVF thrombosis in adult HD patients.
  • METHODS: 60 HD patients and 22 healthy controls were included.
  • RESULTS: Mean plasma sEPCR levels were significantly higher in HD patients than they were in controls.
  • CONCLUSION: This is the first study to analyze sEPCR levels in HD patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Kidney Failure, Chronic / blood. Kidney Failure, Chronic / therapy. Male. Middle Aged. Renal Dialysis

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17570903.001).
  • [ISSN] 1421-9670
  • [Journal-full-title] American journal of nephrology
  • [ISO-abbreviation] Am. J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / PROCR protein, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


61. Slovacek L, Slovackova B, Jebavy L, Macingova Z: Psychosocial, health and demographic characteristics of quality of life among patients with acute myeloid leukemia and malignant lymphoma who underwent autologous hematopoietic stem cell transplantation. Sao Paulo Med J; 2007 Nov 1;125(6):359-61
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychosocial, health and demographic characteristics of quality of life among patients with acute myeloid leukemia and malignant lymphoma who underwent autologous hematopoietic stem cell transplantation.
  • METHODS: The Czech version of the international generic European Quality-of-Life questionnaire (EQ-5D) was applied to evaluate QOL among patients with acute myeloid leukemia (AML) and malignant Hodgkins and non-Hodgkins lymphoma (ML).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / psychology. Hodgkin Disease / surgery. Leukemia, Myeloid, Acute / therapy. Lymphoma, Non-Hodgkin / surgery. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Analysis of Variance. Czech Republic. Educational Status. Female. Health Surveys. Humans. Male. Middle Aged. Retrospective Studies. Smoking / adverse effects. Surveys and Questionnaires. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317610.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


62. Segura-Ortí E: [Exercise in haemodyalisis patients: a literature systematic review]. Nefrologia; 2010;30(2):236-46
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ejercicio en pacientes en hemodiálisis: revisión sistemática de la literatura.
  • Exercise as a therapeutic tool used in End-stage renal disease patients (ESRD) in hemodialysis (HD) is not routinately applied, as it occurs with cardiac or respiratory patients.
  • 1) to systematically review the literature of exercise training on adult HD patients or patients at a pre-HD stage;.
  • 3) to recommend requirements of future research in order to include exercise prescription in the HD patients treatment.
  • Randomized Controlled Trials on aerobic, strength and combined programs for HD patients were selected.
  • Future studies should clarify which out of the three modalities results in higher benefits for HD patients.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Exercise. Exercise Tolerance. Female. Humans. Male. Middle Aged. Oxygen Consumption. Quality of Life. Randomized Controlled Trials as Topic / statistics & numerical data. Research Design. Resistance Training. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098466.001).
  • [ISSN] 0211-6995
  • [Journal-full-title] Nefrología : publicación oficial de la Sociedad Española Nefrologia
  • [ISO-abbreviation] Nefrologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Number-of-references] 50
  •  go-up   go-down


63. Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR: Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem; 2005 Oct;95(1):210-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.
  • Huntington disease (HD) is an adult onset neurodegenerative disorder characterized by selective atrophy and cell loss within the striatum.
  • Transglutaminase (TG) activity is increased in HD patients, is associated with cell death, and has been suggested to contribute to striatal neuronal loss in HD.
  • Specifically, we examine the effect of cystamine on striatal neuronal loss in the YAC128 mouse model of HD.
  • While the exact mechanism responsible for the beneficial effects of cystamine in YAC128 mice is uncertain, our findings suggest that cystamine is neuroprotective and may be beneficial in the treatment of HD.
  • [MeSH-major] Cystamine / pharmacology. Huntington Disease / pathology. Huntington Disease / physiopathology. Mutation. Nerve Tissue Proteins / genetics. Neuroprotective Agents / pharmacology. Nuclear Proteins / genetics
  • [MeSH-minor] Administration, Oral. Animals. Corpus Striatum / pathology. Disease Models, Animal. Drug Administration Schedule. Mice. Mice, Transgenic. Motor Activity / drug effects. Prosencephalon / enzymology. Transglutaminases / metabolism

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181425.001).
  • [ISSN] 0022-3042
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hdh protein, mouse; 0 / Nerve Tissue Proteins; 0 / Neuroprotective Agents; 0 / Nuclear Proteins; EC 2.3.2.13 / Transglutaminases; R110LV8L02 / Cystamine
  •  go-up   go-down


64. Swarnalatha G, Ram R, Neela P, Naidu MU, Dakshina Murty KV: Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress. Saudi J Kidney Dis Transpl; 2010 Sep;21(5):852-8
Hazardous Substances Data Bank. N-ACETYLCYSTEINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the contribution of injectable iron administered to hemodialysis (HD) patients in causing oxidative stress and the beneficial effect of N-acetylcysteine (NAC) in reducing it, we studied in a prospective, double blinded, randomized controlled, cross over trial 14 adult HD patients who were randomized into two groups; one group received NAC in a dose of 600 mgs twice daily for 10 days prior to intravenous iron therapy and the other group received placebo.
  • We conclude that in our HD patients NAC reduced the oxidative stress before and after the administration of intravenous iron therapy in addition to the endothelial dysfunction induced by this treatment.
  • [MeSH-minor] Adult. Biomarkers / blood. C-Reactive Protein / metabolism. Cross-Over Studies. Double-Blind Method. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Endothelium, Vascular / physiopathology. Female. Glucaric Acid. Humans. India. Infusions, Intravenous. Lipid Peroxidation / drug effects. Male. Malondialdehyde / blood. Middle Aged. Placebo Effect. Plethysmography. Prospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814119.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers; 0 / Ferric Compounds; 0 / Hematinics; 4Y8F71G49Q / Malondialdehyde; 9007-41-4 / C-Reactive Protein; FZ7NYF5N8L / ferric oxide, saccharated; QLZ991V4A2 / Glucaric Acid; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


65. Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, Melilli E, Mantovani W, De Matteis G, Olivieri O, Poli A, Lupo A: Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant; 2010 Dec;25(12):3996-4002
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It has been suggested that hepcidin may be useful as a tool for managing iron therapy in haemodialysis (HD) patients on erythropoiesis-stimulating agents (ESA).
  • METHODS: We used SELDI-TOF mass spectrometry assay to measure serum hepcidin-25 (Hep-25) and hepcidin-20 (Hep-20) in 56 adult HD patients on maintenance ESA to assess their ability to predict haemoglobin (Hb) response after 1 g intravenous iron (62.5 mg ferric gluconate at 16 consecutive dialysis sessions) and their relationship with markers of iron status, inflammation and erythropoietic activity.
  • CONCLUSIONS: Although our study suggests an important role for hepcidin in regulating iron homeostasis in HD patients on ESA, our findings do not support its utility as a predictor of iron needs, offering no advantage over established markers of iron status.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20538788.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP06213
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Biomarkers; 0 / HAMP protein, human; 0 / Hematinics; 0 / Hemoglobins; 0 / Hepcidins; E1UOL152H7 / Iron
  •  go-up   go-down


66. Woog JJ, Kim YD, Yeatts RP, Kim S, Esmaeli B, Kikkawa D, Lee HB, Korn BS, Punja K, Habermann TM, Colgan JP, Salomao D, Cameron JD: Natural killer/T-cell lymphoma with ocular and adnexal involvement. Ophthalmology; 2006 Jan;113(1):140-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer/T-cell lymphoma with ocular and adnexal involvement.
  • PURPOSE: To review the clinical, radiological, and histopathologic features in 8 patients with natural killer/T-cell lymphoma (NKTL) involving the orbit and/or ocular adnexa, and to describe the responses of these patients to various treatment regimens.
  • Therapy consisted of various chemotherapeutic regimens typically employed in the treatment of non-Hodgkins lymphoma, steroids, surgical intervention, and radiation.
  • Seven (87.5%) patients died 5 weeks to 13 months after presentation, and 1 (12.5%) is alive without disease (5-year follow-up).
  • CONCLUSIONS: Natural killer/T-cell orbital lymphoma is a rare Epstein-Barr virus-associated neoplasm that may occur with or without associated sinonasal involvement.
  • [MeSH-major] Eyelid Neoplasms / pathology. Killer Cells, Natural / pathology. Lacrimal Apparatus Diseases / pathology. Lymphoma, T-Cell / pathology. Orbital Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD3 / metabolism. Antigens, CD56 / metabolism. Combined Modality Therapy. Epstein-Barr Virus Infections / metabolism. Epstein-Barr Virus Infections / mortality. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / radiography. Female. Herpesvirus 4, Human / isolation & purification. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360212.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD56
  •  go-up   go-down


67. Lee SM, Buchler T, Bomanji J, Ramsay A, Edwards SG: Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult. AIDS; 2008 Jan 2;22(1):159-60
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. HIV Infections / drug therapy. Hodgkin Disease / complications. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Disease Progression. Fluorodeoxyglucose F18 / metabolism. Humans. Male. Positron-Emission Tomography / methods. Thymus Gland / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090408.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antibiotics, Antineoplastic; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


68. Lokare A, Chaganti S, Lipkin G, Roberts C, Mahendra P: Posttransplant lymphoproliferative disorder followed by Hodgkins disease in a renal transplant recipient. Transplantation; 2008 Apr 27;85(8):1219-20
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplant lymphoproliferative disorder followed by Hodgkins disease in a renal transplant recipient.
  • [MeSH-major] Hodgkin Disease / etiology. Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / etiology
  • [MeSH-minor] Adult. Humans. Male

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431246.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


69. Molin D, Svenska Hodgkingruppen: [The backside of success: Late adverse effects of radiotherapy in Hodgkin lymphoma]. Lakartidningen; 2010 Nov 3-9;107(44):2731-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The backside of success: Late adverse effects of radiotherapy in Hodgkin lymphoma].
  • [Transliterated title] Framgångens baksida: Sena biverkningar av strålbehandling vid Hodgkins lymfom.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Female. Humans. Male. Muscular Atrophy / etiology. Quality of Life. Radiation Injuries / etiology. Radiotherapy Dosage. Risk Factors. Time Factors. Treatment Outcome






Advertisement